None listed
Conditions
Interventions
Medical Device : Dialysis schedule and time is implemented equally in each group. Every dialysis three times a week, four hours during each dialysis will be planned. Although blood flow could be adjus
Sponsors
Pusan National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A person who have maintained hemodialysis for more than three months due to end stage kidney disease and have not changed their drug use for the past mont 2. A person whose hemodialysis access is not a catheter, who can maintain a blood flow rate of more than 250 ml/min 3. A person who have been provided with a description of all matters relating to the study and voluntarily signed and dated prior to participating in the study.
Exclusion criteria
Exclusion criteria: 1. A person whose hemodialysis schedule is not three times per wee. 2. A person who peritoneal dialysis is also conducted with hemodialysis such as hybrid dialysis treatment. 3. A person receiving inpatient treatment to serious disease within the period studied. 4. A person who complain of a severe fluctuation of blood pressure and intractable fatigue during hemodialysis. 5. A person with frequent changes of dry weight and dialysis prescription 6. A persion who maintain dialysis with catheter 7. A person who can't measure blood pressure in upper arm. 8. A person with a malignant tumor history who has a symptom or who has not been diagnosed with a complete cure. 9. pregnant and breastfeeding targets 10. A person who participated in other clinical trials with interventional design. 11. A person who is not suitable for this study according to judgement of investigators 12. A person with vulnerable or limited ability to agree with this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proteomics (blood, dialysate);metabolomics (blood, dialysate) | — |
Secondary
| Measure | Time frame |
|---|---|
| proteomics (dialysis membrane fiber);metabolomics (dialysis membrane fiber);clearance of middle molecules (a1-microglobulin, fetuin A, Fibroblast growth factor-23) | — |
Countries
Korea, Republic of
Contacts
Public ContactHyo Jin Kim
Pusan National University Hospital
Outcome results
None listed